BSTC News and Press, BioSpecifics Technologies Corp From 10/19/20

Endo International (ENDP) has agreed to acquire all of the outstanding shares of BioSpecifics Technologies (BSTC) for $88.50 per share in cash, representing an aggregate equity value of  ~$540M (net of ~$120M in cash acquired).Under the terms of the merger agreement, Endo through a ...

Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™ Canada NewsWire DUBLIN, Oct. 19, 2020 -- Endo to acquire BioSpecifics in an accretive all-cash transaction -- DUBLIN , Oct. 19, 2020 /CNW/ -- Endo International pl...

The following slide deck was published by BioSpecifics Technologies Corp. in conjunction with this Read more ...

WILMINGTON, Del. , Sept. 14, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North Ame...

WILMINGTON, Del. , Sept. 8, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in Nort...

BioSpecifics Tech (NASDAQ: BSTC ) : Q2 Non-GAAP EPS of $0.11 beats by $0.16 ; GAAP EPS of $0.02. Revenue of $3.9M (-55.9% Y/Y) beats by $1.84M . Press Release More news on: BioSpecifics Technologies Corp., Earnings news and commentary, Healthcare stocks news,

WILMINGTON, Del. , Aug. 10, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ®  in North Amer...

Investment Thesis BioSpecifics Technologies Corp. 5-year share price performance. Source: TradingView BioSpecifics ( BSTC ) is a small microcap with a market cap of just $474m and revenues of $38.1m in 2019, but the company is entering an exciting phase in its development with the recent...

Original post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...

WILMINGTON, Del. , July 20, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) (the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in ...